Vascular endothelial growth factor (VEGF) 1 has been reported to play a key role in angiogenic processes under various pathophysiological conditions such as embryonic development, inflammatory diseases, diabetic retinopathy, and tumor growth (1) (2) (3) (4) (5) (6) . Five different splicing variants of VEGF (VEGF 121 , VEGF 145 , VEGF 165 , VEGF 189 , and VEGF 206 ) have been identified so far (7) . The angiogenic activity of VEGF in vivo may be regulated by the gene expression of the VEGF isoforms and their receptors, fms-like tyrosine kinase-1 (Flt-1 ϭ VEGFR-1) (8) and kinase insert domain-containing receptor (KDR ϭ VEGFR-2) (9). However, another important regulation mechanism is extracellular inhibition of activity through complex formation with proteins, which include platelet factor-4 and soluble forms of VEGF receptors (10 -12) . By screening a human chondrocyte cDNA library using a yeast two-hybrid system, we have recently demonstrated that connective tissue growth factor (CTGF) inhibits VEGF 165 -induced in vitro and in vivo angiogenesis through binding to VEGF 165 (13) . CTGF is a member of the CCN (CTGF/cysteine-rich 61/nephroblastomaoverexpressed gene) family and consists of 349 amino acids with four distinct domains, i.e. insulin-like growth factor-binding protein (IGFBP), von Willebrand factor type C repeat (vWFC), thrombospondin type 1 repeat (TSP-1), and COOHterminal (CT) domains (14, 15) . Because both VEGF and CTGF are expressed in physiological conditions including growth plate morphogenesis and wound healing and pathological fibrosis such as hepatic fibrosis and myocardial fibrosis, the angiogenic activity of VEGF under pathophysiological conditions may be controlled by interaction with CTGF. However, this regulation mechanism can be affected by proteinases, since VEGF and CTGF are susceptible to proteolytic degradation. Plasmin is known to digest VEGF 165 and inactivate its angiogenic activity (16) . Several fragments of CTGF have been detected in culture media of various cells (17) , biological fluids such as sera (17) and uterine luminal flushing (18) . However, no information is available for the proteinases that digest CTGF and modulate the angiogenic activity of the VEGF 165 ⅐CTGF complex.
Matrix metalloproteinases (MMPs) are a gene family of structurally and functionally related zinc endopeptidases that consist of 23 different members in human (19) . MMPs play an * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ** To whom correspondence and reprint requests should be addressed. Tel.: 81-3-5363-3763; Fax: 81-3-3353-3290; E-mail: okada@ sc.itc.keio.ac.jp. 1 The abbreviations used are: VEGF, vascular endothelial growth factor; ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; BAEC, bovine aortic endothelial cells; BSA, bovine serum albumin; CT, COOH-terminal; CTGF, connective tissue growth factor; ECM, extracellular matrix; Flt-1, fms-like tyrosine kinase- In the present study, we examined the susceptibility of the VEGF 165 ⅐CTGF complex to six different MMPs including MMP-1 (tissue collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin-1), MMP-7 (matrilysin), MMP-9 (gelatinase B), and MMP-13 (collagenase-3) and assayed the angiogenic activity of the complex after MMP treatment. The data demonstrate for the first time that MMP-1, -3, -7, and -13 selectively degrade CTGF bound to VEGF 165 , which itself is resistant to MMPs, and that the angiogenic activity of VEGF 165 is recovered by dissociation of CTGF fragments from VEGF 165 after digestion.
EXPERIMENTAL PROCEDURES
Preparation of Human Recombinant CTGF-Recombinant CTGF was prepared as described previously (13) . Briefly, CTGF cDNA amplified by PCR from a chondrocyte cDNA library (CLONTECH, Palo Alto, CA) was cloned into pCMVtag4a (Stratagene, La Jolla, CA) and expressed as FLAG-tagged protein. Culture media were harvested 3 days after transfection of the CTGF expression vector into COS-7 cells, concentrated by ultrafiltration, and subjected to anti-FLAG M2-agarose affinity column chromatography (Sigma-Aldrich). Recombinant CTGF was eluted with 6 M urea, washed with 50 mM Tris-HCl (pH 7.5), 3 M NaCl, 10 mM CaCl 2 , 0.05% Brij 35 and dialyzed against 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 10 mM CaCl 2 , 0.05% Brij 35 (TNCB buffer) immediately after elution (13) . Purified CTGF showed two bands of 38 and 35 kDa on silver-stained gels after SDS-PAGE, which correspond to the glycosylated and non-glycosylated forms (13) . The biological activity of recombinant CTGF was confirmed by tube formation assay (13) . Protein concentration was determined using BCA protein assay reagents (Pierce). Aliquots of purified CTGF were radioiodinated according to the method of Fraker and Speck (26) and used for binding assay.
Preparation of Human MMPs and Other Proteinases-The zymogens of MMP-1, -2, -3, -7, -9, and -13 were purified and activated by incubation with p-aminophenylmercuric acetate (Sigma-Aldrich) according to previous methods (27) (28) (29) (30) (31) . Concentrations of MMPs were determined by titration with tissue inhibitors of metalloproteinases as described previously (32, 33) . Recombinant human ADAMTS4 (a disintegrin and metalloproteinase with thrombospondin motifs 4, which is aggrecanase-1) was purified according to our method (33) , and activity was verified in an assay using aggrecan as a substrate (34) . Concentration of ADAMTS4 was determined using BCA protein assay reagents (Pierce). Plasminogen (Sigma-Aldrich) and pro-elastase (Calbiochem) were activated with streptokinase (Calbiochem-Novabiochem) and trypsin (Sigma-Aldrich), respectively.
Preparation of Polyclonal Antibodies-Polyclonal antibodies against the IGFBP and CT domains of CTGF (anti-IGFBP and anti-CT antibodies, respectively) were raised in rabbits by injecting bovine serum albumin (BSA)-conjugated oligopeptides corresponding to the amino acid sequences of the IGFBP domain (residues 83-95, DFGSPAN-RKIGVC) and CT domain (residues 257-273, IRTPKISKPIKFELSGC), respectively. IgG was isolated from the antisera by DEAE-Sephacel column chromatography. Specific reaction to CTGF was demonstrated by immunoblotting of culture media of 293T cells (an immortalized human embryonic kidney cell line) transfected with pCMVtag4a/CTGF plasmid as described previously (13 165 with CTGF at a molar ratio of 1:1 at 4°C for 24 h as described previously (13) . Digestion of the complex was initially examined by incubation of the substrate at 37°C for 24 h with MMPs, ADAMTS4, elastase, or plasmin in an enzyme-to-substrate ratio of 1:30 in TNCB buffer. Because CTGF in the complex was efficiently digested with MMP-1, -3, -7, and -13, time course digestion was performed by incubation of the complex with these MMPs for different periods ranging from 0 to 24 h in the same enzyme-to-substrate ratio. The reactions were terminated with 20 mM EDTA, and the digestion products were analyzed on silverstained gels after SDS-PAGE and by immunoblotting using anti-IGFBP (1 g/ml), anti-CT (1 g/ml), or anti-VEGF antibodies (10 g/ml; Santa Cruz Biotechnology Inc., Santa Cruz, CA) according to our method (30) . CTGF alone was also digested with MMP-1, -3, -7, and -13 at 37°C for 24 h to confirm the digestion of CTGF without complex formation.
NH 2 -terminal Sequence Analyses-CTGF (10 g) was incubated with MMP-1, -3, -7 or -13 at an enzyme-to-substrate ratio of 1:30 at 37°C for 24 h for MMP-1, -3, and -7 and for 4 h for MMP-13 in a total reaction volume of 100 l in TNCB buffer. Reactions were stopped by treatment with 20 mM EDTA, and the digestion products were subjected to SDS-PAGE. Proteins in the gels were transferred to polyvinylidene difluoride membranes and located by staining with 0.1% Coomassie Brilliant Blue R-250. The bands of interest were excised and sequenced by Edman degradation using Procise 491 Protein Sequencer (PerkinElmer Life Sciences) (33) .
Release of CTGF Fragments from the VEGF 165 ⅐CTGF Complex after Digestion with MMPs-Microtiter plates with 96 wells (Immunomodule, NalgeNunc, Rochester, NY) were coated with 50 l of VEGF 165 (500 ng/well) for 16 h at 4°C. Then the plates were washed twice with phosphate-buffered saline (PBS) containing 0.05% Brij 35 and subsequently blocked with 1% BSA in PBS for 2 h at room temperature.
125
I-Labeled CTGF (1ϳ3 ϫ 10 5 cpm, 10 ng/well) was bound to each well by incubation for 24 h at 4°C. After washing carefully twice with PBS containing 0.05% Brij 35, the bound proteins were digested with MMP-3 (1 ng) or MMP-7 (1 ng) in TNCB buffer or buffer alone for 0.5, 4, or 24 h at 37°C. Reaction mixtures were collected, and CTGF fragments were immunoprecipitated with 50 l of anti-IGFBP antibody or anti-CT antibody, which were then trapped onto protein G-Sepharose beads (Amersham Biosciences). CTGF remaining on the wells was dissociated by treatment with 1 N NaOH. Radioactivity of the precipitates and NaOH-dissociated fractions was counted by ␥-counter ARC-600 (Aloka, Tokyo, Japan).
Endothelial Cell Tube Formation Assay-Tube formation assay using bovine aortic endothelial cells (BAEC) in type I collagen gel was carried out as described previously (13) . Briefly, type I collagen (3 mg/ml) (Vitrogen, Cohesion, Palo Alto, CA) was mixed with 10-fold concentrated M199 (Invitrogen) and 0.1 N NaOH at a ratio of 8:1:1, respectively. The mixture (500 l) was dispensed to 24-well culture plates and incubated at 37°C for 1 h to form collagen fibrils. BAEC were trypsinized and plated on the collagen gel at a density of 5 ϫ 10 4 cells/well. They were cultured in M199 medium supplemented with 10% fetal bovine serum overnight. After removal of the media, 500 l of the collagen mixture was overlaid on the cells and incubated for 1 h at 37°C. The cells were stimulated for 3 days with VEGF 165 , CTGF, VEGF 165 ⅐CTGF complex, VEGF 165 ⅐CTGF complex digested with MMPs or MMPs by adding media containing these molecules onto the top of the collagen gel layers. For VEGF 165 ⅐CTGF complex formation, VEGF 165 (40 ng) was incubated for 24 h at 4°C with increasing concentrations of CTGF (40 and 200 ng and 1 g) in M199 medium containing 1% fetal bovine serum. Digestion mixtures of the complex, which were made by incubation of VEGF 165 (40 ng) with CTGF (100 ng) for 24 h at 4°C, were prepared by digestion of the complex with MMP-1, -3, and -13 (3 ng each) for 24 h at 37°C. To demonstrate that recovered angiogenic activity after digestion of the VEGF 165 ⅐CTGF complex with MMP-1, -3, or -13 is derived from VEGF 165 , the MMP digestion mixtures prepared as mentioned above were incubated with 40 g of mouse monoclonal anti-VEGF IgG (Upstate Biotechnology, Lake Placid, NY) or non-immune mouse IgG (DAKO, Glostrup, Denmark) for 1 h at 37°C and then used for tube formation assay. As for a control, the cells were also stimulated with CTGF (100 ng) or CTGF (100 ng) digested with MMP-1, -3, or -13 (3 ng each) for 24 h at 37°C. After 3 days of culture, each well was photographed, and the tubular length of the cells was measured in five different areas in 0.25 mm 2 using NIH Image 1.62 as described previously (13) . The length was expressed as mm/mm 2 . Experiments were repeated three times, and similar results were obtained.
In Vivo Angiogenesis Assay-In vivo angiogenesis assay using a Matrigel injection model was performed as previously described (13) . Before injection, 500 l of Matrigel (Collaborative Biomedical Products, Bedford, MA) was mixed with 50 l of PBS, VEGF 165 (50 ng), VEGF 165 (50 ng)-CTGF (100 ng) complex, complex digested with MMP-3 (3 ng) for 24 h at 37°C, MMP-3 digestion mixture incubated with anti-VEGF IgG (50 g; Upstate Biotechnology) or non-immune mouse IgG (50 g; DAKO) for 1 h at 37°C, CTGF (100 ng), CTGF (100 ng) digested with MMP-3 (3 ng) for 24 h at 37°C, or MMP-3 (3 ng). MMP-3 activity was inactivated before mixing with Matrigel by incubation with sheep polyclonal anti-human MMP-3 IgG (0.5 g) (35) . Matrigel containing these factors was injected subcutaneously near the abdominal midline of 4-week-old male C57BL/6J mice. Cutaneous tissues with Matrigel plugs were removed 5 days after injection, fixed in periodate-lysine-paraformaldehyde, and embedded in paraffin. The serial sections were stained with hematoxylin and eosin and immunostained with rabbit anti-vWF antibody (1:200; DAKO) or non-immune rabbit IgG. The degree of angiogenesis was determined by counting vWF-positive cells and blood vessels with an apparent luminal area/mm 2 area using NIH Image 1.62 according to our previous method (13) .
Statistical Analysis-Measured values were expressed as mean Ϯ S.D. In the tube formation assay, the difference of tubular length treated with VEGF 165 and VEGF 165 ⅐CTGF complex was analyzed by Bonferroni/Dunn test. In the in vivo angiogenesis assay, the differences of spindle cells and blood vessels between two independent groups were analyzed by the Mann-Whitney test. These tests were performed using StatView 5.0. p values of less than 0.05 were considered significant. 165 by CTGF-Our previous studies (13) have demonstrated that the angiogenic activity of glycosylated VEGF 165 is inhibited with CTGF by in vitro and in vivo assays. To further confirm the inhibitory effect of CTGF on the angiogenic activity of non-glycosylated recombinant VEGF 165 used in the present study, the activity was assayed by tube formation assay. As shown in Fig. 1, A and B, VEGF 165 stimulated the tubular extension 5.5-fold more than the untreated control. In contrast, VEGF 165 -induced tube formation was remarkably reduced in the presence of CTGF. Increasing concentrations of CTGF inhibited the activity with a peak at 200 ng/ml. These data are consistent with our previous data of CTGF inhibition of angiogenesis using glycosylated VEGF 165 (13) , indicating that glycosylated chains of VEGF 165 are not involved in the inhibitory effect of CTGF. 165 and CTGF were complexed by incubating them at a molar ratio of 1:1 for 16 h at 4°C, and then the complex was digested at 37°C for 24 h with 6 different MMPs (MMP-1, -2, -3, -7, -9, and -13), ADAMTS4, elastase, or plasmin. When the reaction products of the VEGF 165 ⅐CTGF complex with MMPs were analyzed on silver-stained gels, CTGF of 35 and 38 kDa was cleaved by MMP-1, -3, -7, and -13 into a few fragments with lower molecular weights ranging from 19 to 23 , or plasmin (lane 10) for 24 h at 37°C as described under "Experimental Procedures." After termination of the reaction, the digestion products were subjected to SDS-PAGE (15% total acrylamide) under reduction and analyzed by immunoblotting using anti-IGFBP (A), anti-CT (B), and anti-VEGF antibodies (C). Lane 1 is the control incubated with buffer alone for 24 h at 37°C. kDa (data not shown). However, because VEGF 165 of 19 kDa co-migrated with these fragments, some digestion fragments could not be differentiated from VEGF 165 . On the other hand, when the reaction mixtures were analyzed by immunoblotting with two different anti-CTGF antibodies specific to the IGFBP domain or CT domain, intact CTGF disappeared, and several 19ϳ23-kDa bands immunoreactive with these antibodies were observed in the digestion products with MMP-1, -3, -7, and -13 (Fig. 2, A and B) . In addition, weak immunoreactive bands were also detected by digestion with MMP-2 and MMP-9 (Fig.  2, A and B) , although they were not detectable on silver-stained gels (data not shown). CTGF was also digested by elastase and plasmin into small peptides, most of which were not observed by immunoblotting with antibodies (Fig. 2, A and B) , or on a silver-stained gel (data not shown). However, CTGF was resistant to ADAMTS4 (Fig. 2, A and B) . In contrast to the susceptibility of CTGF to MMPs, VEGF 165 was completely resistant to digestion with MMPs and ADAMTS4 under these conditions, whereas both elastase and plasmin cleaved VEGF 165 of 19 kDa into 13-kDa fragments (Fig. 2C) .
RESULTS

Inhibition of Angiogenic Activity of VEGF
Digestion of VEGF 165 ⅐CTGF Complex by MMPs or Other Proteinases-VEGF
Time Course Digestion of VEGF 165 ⅐CTGF Complex by  MMP-1, -3, -7 , and -13-To compare the susceptibility of the VEGF 165 ⅐CTGF complex to degradation with MMP-1, -3, -7, and -13, all of which digested CTGF in a 24-h incubation, time course digestion was carried out and monitored by immunoblotting with anti-CT antibody. Among the four MMPs examined, MMP-13 appeared to most efficiently digest CTGF in the complex, since intact CTGF was degraded fastest. A complete digestion of CTGF was observed after a 4-h incubation with MMP-13 ( Fig. 3D) and after an 8-h incubation with MMP-3 (Fig. 3B) . However, MMP-1 and MMP-7 required a 24-h incubation (Fig. 3, A and C) .
Determination of CTGF Cleavage Sites by MMPs-When CTGF alone was digested with MMP-1, -3, -7, and -13 and the digestion patterns of CTGF were compared with those obtained by VEGF 165 ⅐CTGF complex digestion with MMPs, the fragments detected with anti-IGFBP and anti-CT antibodies were identical between the samples of CTGF alone and VEGF 165 ⅐CTGF complex (data not shown). Thus, NH 2 -terminal sequence analyses of the CTGF fragments generated by digestion with MMP-1, -3, -7, and -13 were performed by incubation of CTGF alone with MMPs. As shown in Table I , the NH 2 -terminal sequences of the COOH-terminal fragments of CTGF were successfully determined. However, the NH 2 -terminal sequence of intact CTGF was not obtained, indicating that its NH 2 terminus is blocked. Besides intact CTGF, the NH 2 -terminal sequences of several 19ϳ23-kDa CTGF fragments recognized with anti-IGFBP antibody could not be obtained, suggesting that these fragments contain the NH 2 (Fig. 4A) . The radioactivity of 125 I-CTGF bound to VEGF 165 on the wells decreased with time of MMP-3 digestion and reached almost background levels after 4-and 24-h incubations (Fig. 4B) , suggesting dissociation and release of the CTGF digestion fragments into the supernatant. In accordance with our prediction, immunoprecipitation of the NH 2 -and COOH-terminal 125 I-CTGF fragments with anti-IGFBP and anti-CT antibodies demonstrated that radioactivity of fragments increases in the liquid phase, and the sum of the radioactivity is nearly equal to that bound to VEGF 165 after a 24-h incubation (Fig. 4B) . Similar results were obtained in digestion experiments using MMP-7 (data not shown). By buffer incubation of the complex on the wells in the absence of MMP-3 or MMP-7, release of the radioactivity was only negligible at each incubation time (data not shown). Thus, these data indicate that both MMPs digest CTGF and dissociate its fragments from the VEGF 165 complex with MMP-1,  -3, -7, and -13 . Digestion of the VEGF 165 ⅐CTGF complex was performed by incubation with MMP-1 (A), -3 (B), -7 (C), or -13 (D) at 37°C for 0 -24 h as described under "Experimental Procedures." After termination of the reaction, the digestion products were analyzed by immunoblotting using anti-CT antibody.
the VEGF 165 ⅐CTGF complex treated with MMP-1, -3, and -13 was assayed by tube formation assay. VEGF 165 -mediated stimulation of endothelial tubular extension was significantly inhibited by complex formation with CTGF (Fig. 5, A, 1-3, and B) . However, when the complex was digested with MMP-1, -3, or -13 and then the digestion products were applied to the tube formation assay, angiogenic activity recovered to the original levels obtained by VEGF 165 treatment (Fig. 5, A, 4-6, and B) . The MMPs themselves showed no definite effects on tube formation (Fig. 5, A, 7-9, and B) . CTGF alone tended to have weak angiogenic activity, although the activity was not significantly different from the buffer control (Fig. 5C ). However, CTGF fragments prepared by the digestion of CTGF alone with MMP-1, -3, or -13 exhibited no definite angiogenic activity (see Fig. 5C for digestion with MMP-3; data not shown for digestion with MMP-1 or MMP-13). To further demonstrate that VEGF 165 is responsible for the reactivated angiogenic activity in the MMP-cleaved VEGF 165 ⅐CTGF complex, the effect of anti-VEGF IgG on the tube formation activity was examined. As shown in Fig. 5D , the recovered angiogenic activity in the MMP-3-digested VEGF 165 ⅐CTGF complex was significantly inhibited to the level of the VEGF 165 ⅐CTGF complex, whereas non-immune IgG treatment had no inhibitory effect.
Recovery of in Vivo Angiogenic Activity of the VEGF 165 ⅐CTGF Complex after Digestion with MMP-3-To further study the effect of MMP digestion of the VEGF 165 ⅐CTGF complex on in vivo angiogenesis, a Matrigel injection model was used. VEGF 165 in Matrigel remarkably stimulated migration of the spindle-shaped cells and blood vessels with lumina as compared with control without growth factor (Fig. 6A, 1 and 2) . VEGF 165 -induced blood vessels often reached the middle of the plugs and appeared to be dilated. Most of the spindle-shaped cells and the vessel-forming cells within the plugs were strongly immunostained with anti-vWF antibody but negative with non-immune rabbit serum (Fig. 6A, 8 and 9 ). The numbers of the vWF-positive spindle-shaped cells and blood vessels in Matrigel were significantly higher by 6.4-fold in samples with VEGF 165 (300 Ϯ 50 cells/mm 2 and 122 Ϯ 16 vessels/mm 2 ) than in those of control (47 Ϯ 7 cells/mm 2 and 19 Ϯ 6 vessels/mm 2 ) (Fig. 6, B and C) . CTGF significantly inhibited the angiogenic activity of VEGF 165 to 28 and 47% of the original activity (84 Ϯ 18 cells/mm 2 and 57 Ϯ 9 vessels/mm 2 ) (Fig. 6, A (3) , B, and C), although CTGF itself showed weak effects on in vivo angiogenesis (63 Ϯ 11 cells/mm 2 and 29 Ϯ 5 vessels/mm 2 ) (Fig. 6, A (5) , B, and C). More importantly, the digestion product of the VEGF 165 ⅐CTGF complex with MMP-3, but not the CTGF fragments prepared by digestion of CTGF alone with MMP-3, significantly increased 3.7-and 2.4-fold the angiogenic activity (314 Ϯ 64 cells/mm 2 and 136 Ϯ 36 vessels/mm 2 ) as compared with that of the VEGF 165 ⅐CTGF complex (Fig. 6, A (4, 8, and 9) , B, and C). This reactivation of the angiogenic activity in the MMP-3-digested VEGF 165 ⅐CTGF complex was inhibited to the level of the complex by the treatment with anti-VEGF IgG (110 Ϯ 18 cells/mm 2 and 72 Ϯ 10 vessels/mm 2 ) (Fig. 6, A (6) , B, and C). MMP-3 inactivated with polyclonal anti-MMP-3 IgG showed no effects on in vivo angiogenesis (50 Ϯ 6 cells/mm 2 and 23 Ϯ 4 vessels/mm 2 ) (Fig. 6, A (7) , B, and C).
DISCUSSION
In the present study, we have demonstrated for the first time that all six different MMPs, i.e. MMP-1, -2, -3, -7, -9, and -13, can selectively degrade CTGF in the VEGF 165 ⅐CTGF complex, although the proteolytic activity of MMP-2 and MMP-9 to CTGF was very weak. Because these MMPs produced identical digestion fragments by incubation with CTGF alone, the degradation can be ascribed to the specific recognition of CTGF substrate and its subsequent proteolysis by MMPs. The primary substrates of MMPs are thought to be ECM macromolecules, but this study indicates that growth factor is also a substrate of many MMPs. Actually, accumulated lines of evidence have indicated that MMPs can cleave various molecules other than ECM components such as MCP-3, interleukin-1␤, Fas ligand, and IGFBP-3 (21-24). Our data on the NH 2 -terminal sequences of the CTGF fragments generated by digestion -terminal sequences of the COOH-terminal fragments generated by digestion with MMP-1, -3, -7, and -13 with MMP-1, -3, -7, and -13 demonstrate that the residues in the P1Ј position are Leu, Ile, and Tyr, all of which are the common residues found in the P1Ј position for the ECM and non-ECM substrates of MMPs (20 -22,36) . In contrast to the MMPs, ADAMTS4, which cleaves almost selectively the Glu-X bonds of aggrecan (37) preferentially degrades ECM substrates (38) . However, this was not the case with CTGF digestion, since time course digestion showed that MMP-7 appears to have weaker activity than MMP-13 and MMP-3. The reason is not clear in the present study. However, because one of the most prominent structural differences of MMP-7 from other MMPs is the lack of the COOH-terminal hemopexin-like domain, that plays a key role in the binding to their substrates (39) , the COOH-terminal domains of MMP-13 and MMP-3, in addition to their catalytic domains, may be required for efficient digestion of CTGF.
Although CTGF was susceptible to the MMPs examined, cleavage was limited to the bonds located in the linker region between the vWFC and TSP-1 domains. Thus, the digestion resulted in the formation of the major NH 2 -and COOH-terminal fragments of ϳ20 kDa. This contrasts to the digestion patterns with leukocyte elastase and plasmin, since they degraded CTGF into small peptides by cleaving at multiple sites after a 24-h incubation. Previous immunoprecipitation studies (17) show that human biological fluids such as sera, cerebrospinal fluids, and ascites contain CTGF degradation fragments of 32, 24, and 18 kDa as well as intact 38-kDa CTGF. These fragments are also detected in the culture media from human breast cancer cells (17) . Because the molecular sizes of the latter two fragments are similar to those found after digestion with MMPs and such biological fluids and culture media usually contain MMPs, it might be possible to speculate that the 24-and 18-kDa fragments are generated by digestion of CTGF with MMPs. The COOH-terminal fragments of 10 kDa, which stimulate DNA synthesis in fibroblasts and smooth muscle cells (18) , have been purified from pig uterine luminal flushing (18) and culture media of mouse and human fibroblasts (40) . In the present study, however, such fragments were not identified by digestion with MMPs, leukocyte elastase, or plasmin. Thus, another proteinase(s) than the MMPs and the neutrophil serine proteinases may be involved in the formation of the bioactive 10-kDa fragments.
VEGF 165 is known to be susceptible to degradation by plasmin, trypsin, chymotrypsin, clostripain, and bromelain (16) . The present study confirmed the data of VEGF 165 digestion with plasmin but further showed that it is also cleaved by leukocyte elastase. Digestion with these serine proteinases produced a major VEGF 165 fragment with a molecular mass ϳ6 kDa lower than recombinant VEGF 165 under reducing conditions. Although the present study did not determine the NH 2 -terminal sequence of the fragment, the molecular size suggests that the fragment is generated through the cleavage at the Arg 110 -Ala 111 bond of VEGF 165 by plasmin as reported by Keyt et al. (16) . In contrast to the effect of the serine proteinases, our study demonstrated that VEGF 165 is completely resistant to all the six MMPs examined. These results are in accordance with the finding that serine proteinase activity but not metalloproteinase activity in the wound fluid from chronic ulcers is responsible for the degradation of VEGF 165 (41) .
One of the most important findings in the present study is that angiogenic activity of VEGF 165 , which was suppressed by the complex formation with CTGF, recovered after digestion of CTGF in the VEGF 165 ⅐CTGF complex with MMPs. Our previous study demonstrated that CTGF inhibits VEGF 165 -induced angiogenesis by interrupting the binding of VEGF 165 to its major receptor VEGFR-2 through complex formation between the exon 7-coded region of VEGF 165 and the TSP-1 domain of CTGF (13) . Thus, the dissociation of CTGF fragments from the VEGF 165 ⅐CTGF complex after MMP digestion is essential to the recovery of angiogenic activity. In the present study, we have demonstrated that the NH 2 -and COOH-terminal fragments of CTGF are dissociated and released from the complex by digestion with MMP-3 and MMP-7. Because these MMPs cleave the linker region of CTGF between the vWFC and TSP-1 domains without attacking the binding site (the TSP-1 domain), conformational changes of CTGF caused by digestion appear to be responsible for dissociation. Our previous and present studies showed that CTGF itself is an angiogenic factor. However, the maximal activity of CTGF was weak and confined to only ϳ25 and ϳ35% that of VEGF 165 in in vitro tube formation assay and in in vivo Matrigel injection assay, respectively (13) . In addition, our data in the present study could demonstrate that the CTGF digestion fragments by MMPs have no angiogenic activity in in vitro and in vivo angiogenesis assays. The data are accordant with the previous finding that the bioactive 10-kDa COOH-terminal CTGF fragment cannot stimulate endothelial cells (18) . Furthermore, angiogenic activity recovered from the VEGF 165 ⅐CTGF complex after digestion with MMPs was blocked with anti-VEGF antibody. It is, therefore, concluded that reactivation of the angiogenic activity in the MMP-digested VEGF 165 ⅐CTGF complex is ascribed to the effect of VEGF 165 dissociated from the complex on endothelial cells.
Because of the overexpression of CTGF in tissues undergoing fibrosis and its stimulatory activity toward fibroblasts to proliferate and synthesize ECM, CTGF is believed to play a key role in pathological fibrosis such as hepatic fibrosis, atherosclerosis, and myocardial fibrosis (42) (43) (44) . CTGF is also expressed in the processes of wound healing (41, 45) , where granulation with neovascularization precedes the final scar formation. Interestingly, MMPs are overproduced in the active angiogenic stages in these pathophysiological conditions (46) . Thus, we hypothesize that in the angiogenic stage of these conditions, activity of the VEGF 165 ⅐CTGF complex is in favor of VEGF 165 by degradation of CTGF with MMPs, and then in the fibrotic stage, angiogenic activity is blocked by complex formation with CTGF because of decreased MMP activity. In cartilage, VEGF, CTGF, and MMPs including MMP-3 are produced in the hypertrophic chondrocytes of the growth plate (47) (48) (49) (50) . Because the activity of VEGF is essential to the remodeling of the growth plate (47), a similar regulation mechanism of the VEGF⅐CTGF complex by MMPs might be involved in this process. A previous study on MMP-9-deficient mice indicated that development of the growth plate is transiently retarded due to impaired angiogenesis (51) . Because MMP-9 weakly digests CTGF in the VEGF 165 ⅐CTGF complex, it might be possible to speculate that this transient phenotype is caused by decreases in the CTGF degradation and subsequent VEGF release from the complex by an action of MMP-9 in the early developmental stages of the mice before other MMPs compensate for the lack of MMP-9. Articular cartilage is an avascular tissue, but diseased cartilage is invaded by pannus tissue, which is a granulation tissue with hypervascularity (52) . VEGF, CTGF, and MMPs are all expressed in the articular cartilages from patients with osteoarthritis or rheumatoid arthritis (20, 53) . 2 Thus, angiogenic activity of VEGF, which is probably inhibited by VEGF⅐CTGF complex formation in normal articular cartilage, may be reactivated by CTGF degradation with MMPs overproduced in such joints, allowing the pannus tissue to invade the cartilage. These hypotheses on the in vivo proteolytic regulation of the VEGF⅐CTGF complex by MMPs remain to be further studied at the cellular and tissue levels.
